Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than females and is attributed to historical differences in exposures with world-standardised incidence rates per 100 000 persons of 0.7 and 0.3 in the United States and 1.7 and 0.4 for Europe (for males and females, respectively). Incidence is highest in countries with greatest previous asbestos use such as the Netherlands, UK and Australia.1 Due to a lag time of ∼40 years between exposure and presentation, alongside relatively recent usage bans, incidence continues to rise in many countries.